Viatris (VTRS) FY2024 10-K Annual Report
Viatris (VTRS) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Feb 27, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Viatris FY2024 10-K Analysis
Business Overview
- • Core business model focused on pharmaceutical manufacturing, supply chain, and commercial operations with continued divestiture activity
- • Recent divestitures include Biocon Biologics Transaction, OTC products, women’s healthcare, and API business segments emphasized this year
Management Discussion & Analysis
- • No revenue or profitability figures reported in provided MD&A excerpt
- • No segment performance data included in given text
Risk Factors
- • FDA warning letter and import alert on Indore, India facility, blocking 11 products from U.S., 2025 revenue impact approx. $500M, earnings impact $385M
- • Exposure to geopolitical conflicts including Russia-Ukraine and Middle East impacting supply chains and economic conditions in Emerging Markets
Viatris FY2024 Key Financial MetricsXBRL
Revenue
$14.7B
▼ -4.5% YoY
Net Income
-$634M
▼ -1259.4% YoY
Gross Margin
38.3%
▼ -357bp YoY
Operating Margin
0.1%
▼ -491bp YoY
Net Margin
-4.3%
▼ -467bp YoY
ROE
-3.4%
▼ -367bp YoY
Total Assets
$41.5B
▼ -13.0% YoY
EPS (Diluted)
$-0.53
▼ -1160.0% YoY
Operating Cash Flow
$2.3B
▼ -17.7% YoY
Source: XBRL data from Viatris FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Viatris Annual Reports
Get deeper insights on Viatris
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.